Myanmar Health Sciences Research Journal
Volume 28, Number 1
TITLE: Comparison of Serum Epidermal Growth Factor Receptor and Cyclooxygenase-2 Levels in Patients with Non-small Cell Carcinoma of Lung and Normal Subjects
AUTHOR: Thuzar Kyin Aung, Htar Kyi Sunn & Theingi Myint
SOURCE: Myanmar Health Sciences Research Journal, Vol. 28, No. 1, 2016
ABSTRACT: Relation of inflammation and cancer can be proven in most of the studies. Epidermal growth factor receptor (EGFR) overexpression is one of the commonest causes of non-small cell carcinoma of lung cancer (NSCLC). Cyclooxygenase-2 (COX-2) enzyme and its products; prostaglandin, prostacyclin, thromboxane are involved in inflammation. The aim of the study was to compare the serum epidermal growth factor receptor and cyclooxygenase-2 levels between patients with non-small cell carcinoma of lung and healthy controls. This study included 53 patients diagnosed as NSCLC and 16 apparently healthy controls. In 53 patients, 3 patients were diagnosed as adenocarcinoma and 50 patients were diagnosed as squamous cell carcinoma (SCC) of lung. In both subjects, serum EGFR and COX-2 levels were determined by ELISA. The mean serum EGFR and COX-2 levels of NSCLC patients were significantly higher than those of healthy controls (170.10±13.80 vs. 3.56±0.48 ng/ml) and (13.21±3.17 vs. 0.62± 0.15 ng/ml), respectively (p<0.001 in both). Both the mean serum EGFR and COX-2 levels of SCC patients (172.10±14.30 ng/ml and 13.60±3.34 ng/ml) were significantly higher than those of healthy controls (p<0.001 in both). Both serum EGFR levels and COX-2 levels of patients with adeno-carcinoma of lung (137.40±64.70 ng/ml and 6.69±5.52 ng/ml) were not significantly different with those of healthy controls (p=0.174 and =0.386),respectively. The mean serum EGFR and COX-2 levels of SCC patients were higher than those of adenocarcinoma patients but they were not significant (p=0.653 and p=0.363), respectively. These findings indicated that EGFR and COX-2 play an important role in carcinogenesis of lung.
SUBJECT HEADINGS: Epidermal growth factor receptor, Cyclooxygenase-2, Non-small cell carcinoma of lung, Prostaglandin